Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005813 · ClinicalTrials.gov registry record · Phase 1
Bispecific Antibody Plus White Blood Cells in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme
A Phase 1 study of Brain and Central Nervous System Tumors, sponsored by Dartmouth-Hitchcock Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 1
- Study location
NCT00005813: Completed Phase 1 study of Brain and Central Nervous System Tumors, sponsored by Dartmouth-Hitchcock Medical Center.
NCT00005813 is a Phase 1 study of Brain and Central Nervous System Tumors that has completed, run by Dartmouth-Hitchcock Medical Center. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00005813, a Phase 1 study of Brain and Central Nervous System Tumors, has completed, sponsored by Dartmouth-Hitchcock Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 1
- Study location
Study Summary
RATIONALE: Bispecific antibodies plus white blood cells may be able to locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase I trial to study the effectiveness of combining bispecific antibodies with white blood cells in treating patients who have recurrent or refractory glioblastoma multiforme.
Conditions Studied
Interventions
- PROCEDURE conventional surgery
- BIOLOGICAL bispecific antibody MDX447
- BIOLOGICAL lymphokine-activated killer cells
Study Locations (1)
New Hampshire
- Dartmouth-Hitchcock Medical Center - Lebanon
Trial Details
| Field | Value |
|---|---|
| Start Date | 1997-03 |
| Est. Completion | 2003-01 |
| Phase | Phase 1 |
What the finished NCT00005813 record still lists
NCT00005813 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 1 condition, with Brain and Central Nervous System Tumors appearing as the primary indexed condition, and to 3 interventions - of which conventional surgery is the first listed.
NCT00005813 reports a single indexed study location in New Hampshire.
Frequently Asked Questions
What is clinical trial NCT00005813 about?
NCT00005813 is a clinical study titled "Bispecific Antibody Plus White Blood Cells in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme". RATIONALE: Bispecific antibodies plus white blood cells may be able to locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase I trial to study the effectiveness of combining bispecific antibodies with white blood cells in tre...
What is the current status of trial NCT00005813?
This trial is currently completed. It is a Phase 1 study. The study started on 1997-03. Estimated completion is 2003-01.
What conditions does trial NCT00005813 study?
This clinical trial studies the following conditions: Brain and Central Nervous System Tumors.
What interventions are being tested in trial NCT00005813?
The interventions under investigation include: conventional surgery (PROCEDURE), bispecific antibody MDX447 (BIOLOGICAL), lymphokine-activated killer cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT00005813?
This trial is sponsored by Dartmouth-Hitchcock Medical Center, which has 427 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00005813 being conducted?
This trial has 1 study location across New Hampshire. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain and Central Nervous System Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Immunotoxin Therapy in Treating Patients With Malignant Glioma
COMPLETED · Phase 1
-
Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment
COMPLETED · Phase 1
-
SCH 66336 in Treating Children With Recurrent or Progressive Brain Tumors
COMPLETED · Phase 1
-
Sirolimus in Treating Patients With Glioblastoma Multiforme
COMPLETED · Phase 1
-
Tetra-O-Methyl Nordihydroguaiaretic Acid in Treating Patients With Recurrent High-Grade Glioma
COMPLETED · Phase 1
-
Mafosfamide in Treating Patients With Progressive or Refractory Meningeal Tumors
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia